Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force.

PubWeight™: 1.72‹?› | Rank: Top 3%

🔗 View Article (PMID 9307263)

Published in Ann Neurol on September 01, 1997

Authors

R Rudick1, J Antel, C Confavreux, G Cutter, G Ellison, J Fischer, F Lublin, A Miller, J Petkau, S Rao, S Reingold, K Syndulko, A Thompson, J Wallenberg, B Weinshenker, E Willoughby

Author Affiliations

1: Mellen Center, Cleveland Clinic Foundation, OH 44106, USA.

Associated clinical trials:

Domperidone in Secondary Progressive Multiple Sclerosis (SPMS) | NCT02308137

A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | NCT02587806

A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | NCT02587715

A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | NCT02418325

Articles citing this

Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol (2010) 2.96

Association of Cortical Lesion Burden on 7-T Magnetic Resonance Imaging With Cognition and Disability in Multiple Sclerosis. JAMA Neurol (2015) 2.18

Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Mult Scler (2012) 1.75

"Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry (1998) 1.56

A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry (2005) 1.50

Sensorimotor dysfunction in multiple sclerosis and column-specific magnetization transfer-imaging abnormalities in the spinal cord. Brain (2009) 1.38

Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. Ther Adv Neurol Disord (2010) 1.34

Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection. J Neuroophthalmol (2011) 1.25

Quantitative measures detect sensory and motor impairments in multiple sclerosis. J Neurol Sci (2011) 1.14

Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts. J Neurol Neurosurg Psychiatry (2000) 1.10

Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol (2008) 1.10

Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment. Front Neurol (2016) 1.09

Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review. J Neurol (2009) 1.08

Vision and vision-related outcome measures in multiple sclerosis. Brain (2014) 1.08

Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol (2015) 1.05

Treatment of cognitive impairment in multiple sclerosis: position paper. J Neurol (2012) 1.04

Variations in functioning and disability in multiple sclerosis. A two-year prospective study. J Neurol (2008) 1.03

European validation of a standardized clinical description of multiple sclerosis. J Neurol (2004) 0.96

Rasch analysis of the Multiple Sclerosis Impact Scale MSIS-29. Health Qual Life Outcomes (2009) 0.95

Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS One (2014) 0.94

A population-based study of depressive symptoms in multiple sclerosis in Stockholm county: association with functioning and sense of coherence. J Neurol Neurosurg Psychiatry (2006) 0.94

Influence of corpus callosum damage on cognition and physical disability in multiple sclerosis: a multimodal study. PLoS One (2012) 0.92

The Multiple Sclerosis Performance Test (MSPT): an iPad-based disability assessment tool. J Vis Exp (2014) 0.92

Tract-specific quantitative MRI better correlates with disability than conventional MRI in multiple sclerosis. J Neurol (2012) 0.87

Relations of low contrast visual acuity, quality of life and multiple sclerosis functional composite: a cross-sectional analysis. BMC Neurol (2014) 0.84

Correlations between MRI and Information Processing Speed in MS: A Meta-Analysis. Mult Scler Int (2014) 0.83

Corpus callosum microstructural changes correlate with cognitive dysfunction in early stages of relapsing-remitting multiple sclerosis: axial and radial diffusivities approach. Mult Scler Int (2011) 0.83

Natalizumab for the treatment of relapsing multiple sclerosis. Biologics (2008) 0.82

In vivo evidence of glutamate toxicity in multiple sclerosis. Ann Neurol (2014) 0.82

Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials. Mult Scler Int (2014) 0.81

Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves. J Neurol Neurosurg Psychiatry (1999) 0.81

Selecting Rehabilitation Outcome Measures for People with Multiple Sclerosis. Int J MS Care (2015) 0.79

Thalamic lesions in multiple sclerosis by 7T MRI: Clinical implications and relationship to cortical pathology. Mult Scler (2015) 0.79

Determining the Presence of Reliable Change over Time in Multiple Sclerosis: Evidence from the PASAT, Adjusting-PSAT, and Stroop Test. Int J MS Care (2013) 0.78

The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS. BMC Res Notes (2014) 0.77

Influence of multiple sclerosis, age and degree of disability, in the position of the contrast sensitivity curve peak. Indian J Ophthalmol (2014) 0.77

Lesion Heterogeneity on High-Field Susceptibility MRI Is Associated with Multiple Sclerosis Severity. AJNR Am J Neuroradiol (2016) 0.75

Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. Mult Scler (2017) 0.75

Quantitative measures of walking and strength provide insight into brain corticospinal tract pathology in multiple sclerosis. Neuroimage Clin (2017) 0.75

Outcome Measures in Clinical Trials for Multiple Sclerosis. CNS Drugs (2017) 0.75

The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis. Mult Scler (2017) 0.75

Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study. Int J Mol Sci (2015) 0.75

Binocular low-contrast letter acuity and the symbol digit modalities test improve the ability of the Multiple Sclerosis Functional Composite to predict disease in pediatric multiple sclerosis. Mult Scler Relat Disord (2016) 0.75

Health-related quality of life in partners of persons with MS: a longitudinal 10-year perspective. BMJ Open (2014) 0.75

Outcomes After Functional Electrical Stimulation Cycle Training in Individuals with Multiple Sclerosis Who Are Nonambulatory. Int J MS Care (2017) 0.75

Physical activity and cognitive function in adults with multiple sclerosis: an integrative review. Disabil Rehabil (2016) 0.75

Articles by these authors

Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36

A physical map of the human genome. Nature (2001) 12.39

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet (2010) 11.55

Chlamydial infection. Isolation of Chlamydia from patients with non-specific genital infection. Br J Vener Dis (1972) 7.92

Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol (2007) 7.30

E-cadherin germline mutations in familial gastric cancer. Nature (1998) 6.72

Structural basis of cell-cell adhesion by cadherins. Nature (1995) 6.56

Mechanisms of lactose utilization by lactic acid streptococci: enzymatic and genetic analyses. J Bacteriol (1970) 6.34

Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. Cell (1991) 6.28

Spectrographic data concerning vitamin A and liver oils. Biochem J (1931) 6.14

Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev (2000) 5.80

Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature (1992) 5.47

Mechanism of action and development of resistance to a new amidino penicillin. J Bacteriol (1974) 5.47

The antigenic structure of proteins: a reappraisal. Annu Rev Immunol (1984) 5.31

Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit. Cell (1992) 5.29

Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology (2011) 5.16

The Arabidopsis abscisic acid response locus ABI4 encodes an APETALA 2 domain protein. Plant Cell (1998) 4.92

X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli. Science (1999) 4.78

Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology (2007) 4.72

Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 4.41

Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol (1993) 4.23

Rapid diagnosis of pulmonary tuberculosis by using Roche AMPLICOR Mycobacterium tuberculosis PCR test. J Clin Microbiol (1995) 4.11

Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol (1994) 4.07

Neonatal anthropometry: the thin-fat Indian baby. The Pune Maternal Nutrition Study. Int J Obes Relat Metab Disord (2003) 4.06

Recruitment in the Coronary Artery Disease Risk Development in Young Adults (Cardia) Study. Control Clin Trials (1987) 4.05

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med (2000) 3.98

Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol (1999) 3.97

The effectiveness of smoking cessation methods for smokers in public health maternity clinics: a randomized trial. Am J Public Health (1985) 3.91

The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81

Altered electrical properties in Drosophila neurons developing without synaptic transmission. J Neurosci (2001) 3.80

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology (2002) 3.73

Age differences in the frontal lateralization of verbal and spatial working memory revealed by PET. J Cogn Neurosci (2000) 3.66

The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain (2001) 3.51

Chlamydial infections of the cervix. Br J Vener Dis (1974) 3.48

Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology (2005) 3.45

A comparative review of generic quality-of-life instruments. Pharmacoeconomics (2000) 3.42

Causes of childhood blindness: results from west Africa, south India and Chile. Eye (Lond) (1993) 3.40

IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J Immunol (1998) 3.37

Giardia and Cryptosporidium join the 'Neglected Diseases Initiative'. Trends Parasitol (2006) 3.34

Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain (1980) 3.27

Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke (1997) 3.26

Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol (2007) 3.24

The crystal structure of dimeric kinesin and implications for microtubule-dependent motility. Cell (1997) 3.17

Penicillin-sensitive enzymes and penicillin-binding components in bacterial cells. Ann N Y Acad Sci (1974) 3.16

Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene (2006) 3.09

Validity of self-reported colorectal cancer screening behavior. Cancer Epidemiol Biomarkers Prev (2000) 3.07

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol (1995) 3.06

A study of the reliability and comparative validity of the cardia dietary history. Ethn Dis (1994) 3.05

Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics (2001) 3.05

Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med (1990) 2.97

Vitamin B12 and folate concentrations during pregnancy and insulin resistance in the offspring: the Pune Maternal Nutrition Study. Diabetologia (2007) 2.96

Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology (2005) 2.95

Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology (1995) 2.90

Single breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state. Predicted values, lower limits of normal, and frequencies of abnormality by smoking history. Am Rev Respir Dis (1983) 2.83

Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain (2008) 2.83

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology (2006) 2.75

Coma in the Wernicke-Korsakoff syndrome. Lancet (1978) 2.74

Competing demands in the office visit: what influences mammography recommendations? J Am Board Fam Pract (2001) 2.72

Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome. Am J Hum Genet (2001) 2.72

Surgical complication outcome (SCOUT) score: a new method to evaluate quality of care in vascular surgery. J Vasc Surg (1997) 2.67

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 2.66

Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl (2001) 2.66

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med (2000) 2.62

Crystal structure of yeast tRNAAsp. Nature (1980) 2.61

An activating mutation of AKT2 and human hypoglycemia. Science (2011) 2.60

Structure of a cephalosporin synthase. Nature (1998) 2.59

Optical coherence tomography and disease subtype in multiple sclerosis. Neurology (2007) 2.56

The choice of T-cell epitopes utilized on a protein antigen depends on multiple factors distant from, as well as at the determinant site. Immunol Rev (1987) 2.56

Spontaneous mutations in the CsrRS two-component regulatory system of Streptococcus pyogenes result in enhanced virulence in a murine model of skin and soft tissue infection. J Infect Dis (2001) 2.51

Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology (2008) 2.49

Effect of tumor necrosis factor alpha on mitogen-activated human B cells. J Exp Med (1987) 2.42

Antineutrophil cytoplasmic antibodies, cystic fibrosis, and infection. Lancet (1991) 2.41

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol (2001) 2.39

La Crosse encephalitis in children. N Engl J Med (2001) 2.38

Corticosteroid-induced suppression of the hypothalamo-pituitary-adrenal axis: observations on patients given oral corticosteroids for rheumatoid arthritis. Q J Med (1967) 2.38

Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation. J Biol Chem (2000) 2.37

Cell wall and protoplast isoperoxidases in relation to injury, indoleacetic Acid, and ethylene effects. Plant Physiol (1974) 2.36

A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology (2012) 2.34

Quasi-hexagonal molecular packing in collagen fibrils. Nature (1980) 2.28

Oxidation of reduced inorganic sulfur compounds by bacteria: emergence of a common mechanism? Appl Environ Microbiol (2001) 2.28

An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc Natl Acad Sci U S A (2001) 2.28

Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol (1984) 2.25

Vasopressin administration facilitates fluid removal during hemodialysis. Kidney Int (2006) 2.23

Doppler echocardiographic measurement of low velocity motion of the left ventricular posterior wall. Am J Cardiol (1989) 2.23

Automation of sample mounting for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr (2006) 2.22

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med (1987) 2.21

Care of the suddenly bereaved. BMJ (1990) 2.19

The pathophysiology of HOX genes and their role in cancer. J Pathol (2005) 2.18

Issues in the natural history and treatment of coronary heart disease in black populations: surgical treatment. Am Heart J (1984) 2.18

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17

Characterisation of the double genome structure of modern sugarcane cultivars (Saccharum spp.) by molecular cytogenetics. Mol Gen Genet (1996) 2.17

Increase of oleic acid in erythrocytes associated with malignancies. Br Med J (Clin Res Ed) (1985) 2.15

Fine specificity of regulatory T cells. II. Suppressor and helper T cells are induced by different regions of hen egg-white lysozyme in a genetically nonresponder mouse strain. J Exp Med (1979) 2.12

Performance of screening mammography among women with and without a first-degree relative with breast cancer. Ann Intern Med (2000) 2.09